{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:00:00Z","timestamp":1789437600057,"version":"build-2803163510"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Prostate cancer is driven by androgen receptor activation caused by (dihydro)testosterone. Abiraterone, which is used against metastatic castration-resistant prostate cancer (mCRPC), improves survival by irreversibly inhibiting CYP17 to reduce androgen and cortisol synthesis. As such, cortisol is a potential biomarker for androgen suppression. This study assessed the impact of pharmacokinetically (PK)\u2013guided interventions after therapeutic drug monitoring (TDM) of abiraterone on cortisol plasma concentrations as a biomarker for CYP17 inhibition in patients with mCRPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this retrospective cohort study, patients with mCRPC receiving abiraterone with TDM based on abiraterone plasma concentrations were compared with a historical cohort receiving standard care. The primary end point was adequate CYP17 inhibition, defined as cortisol plasma concentration &lt;6.18 nmol\/L. Secondary end points included the time course of cortisol plasma concentrations and the impact of PK-guided interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 103 patients were included in the TDM population, and 99 were included in the historical cohort. Median cortisol plasma concentrations were lower in the TDM population [1.9 (95% confidence interval 1.1\u20135.8) versus 3.9 (95% confidence interval 1.4\u201312.4] nmol\/L,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01), with more patients achieving adequate CYP17 inhibition (75.7% versus 62.6%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.06). Of the 32 patients with evaluable data before and after PK-guided intervention, 96.9% reached adequate abiraterone concentrations; however, no significant improvement in adequate CYP17 inhibition was observed when comparing cortisol before and after PK-guided intervention (81.3% versus 71.9%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.45).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In the TDM population, lower cortisol plasma concentrations were observed. However, it is unclear whether increasing abiraterone exposure through PK-guided interventions decreased cortisol plasma concentrations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001441","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T22:00:07Z","timestamp":1770760807000},"page":"636-643","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Abiraterone Therapeutic Drug Monitoring on Cortisol as a Surrogate Biomarker of CYP17 Inhibition in Metastatic Prostate Cancer Treatment"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1166-529X","authenticated-orcid":false,"given":"Lisanne N.","family":"van Merendonk","sequence":"first","affiliation":[{"name":"Pharmacy and Pharmacology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud B. A.","family":"van der Kleij","sequence":"additional","affiliation":[{"name":"Medical Oncology, the Netherlands Cancer Institute\u2014Antoni van Leeuwenhoek, Amsterdam;"},{"name":"Department Medical Oncology, Erasmus MC Cancer Institute, Rotterdam;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 M.","family":"Bergman","sequence":"additional","affiliation":[{"name":"Medical Oncology, the Netherlands Cancer Institute\u2014Antoni van Leeuwenhoek, Amsterdam;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huub H.","family":"van Rossum","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, the Netherlands Cancer Institute\u2014Antoni van Leeuwenhoek, Amsterdam;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeltje","family":"Steeghs","sequence":"additional","affiliation":[{"name":"Medical Oncology, the Netherlands Cancer Institute\u2014Antoni van Leeuwenhoek, Amsterdam;"},{"name":"Department of Medical Oncology, Utrecht University Medical Centre, Utrecht University, Utrecht;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[{"name":"Pharmacy and Pharmacology and"},{"name":"Department of Pharmacology, Princess M\u00e1xima Center for Pediatric Oncology, Utrecht; and"},{"name":"Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"R1-20260911","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20260911","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/cncr.32039","article-title":"Metastatic castration\u2010sensitive prostate cancer: abiraterone, docetaxel, or","volume":"125","author":"Barata","year":"2019","journal-title":"Cancer"},{"key":"R3-20260911","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"R4-20260911","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"R5-20260911","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J Clin Oncol"},{"key":"R6-20260911","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s40262-014-0178-6","article-title":"Population pharmacokinetic analysis of abiraterone in chemotherapy-na\u00efve and docetaxel-treated patients with metastatic castration-resistant prostate cancer","volume":"53","author":"Stuyckens","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"R7-20260911","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejca.2016.11.027","article-title":"Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients","volume":"72","author":"Carton","year":"2017","journal-title":"Eur J Cancer"},{"key":"R8-20260911","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41391-019-0179-5","article-title":"Exposure-response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer","volume":"23","author":"van Nuland","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R9-20260911","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41416-025-02954-1","article-title":"Feasibility and efficacy of therapeutic drug monitoring of abiraterone in metastatic castration resistant prostate cancer patients","volume":"132","author":"van der Kleij","year":"2025","journal-title":"Br J Cancer"},{"key":"R10-20260911","first-page":"349","article-title":"An exploratory analysis of the association between levels of hormones implied in steroid biosynthesis and activity of abiraterone in patients with metastatic castration-resistant prostate cancer","volume":"69","author":"Bertaglia","year":"2017","journal-title":"Minerva Urol Nefrol"},{"key":"R11-20260911","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jpba.2019.03.043","article-title":"LC-MS\/MS assay for the quantification of testosterone, dihydrotestosterone, androstenedione, cortisol and prednisone in plasma from castrated prostate cancer patients treated with abiraterone acetate or enzalutamide","volume":"170","author":"van Nuland","year":"2019","journal-title":"J Pharm Biomed Anal"},{"key":"R12-20260911","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5489\/cuaj.4303","article-title":"Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer","volume":"11","author":"Klotz","year":"2017","journal-title":"Can Urol Assoc J"},{"key":"R13-20260911","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.urolonc.2019.04.026","article-title":"Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer","volume":"37","author":"Hashimoto","year":"2019","journal-title":"Urol Oncol"},{"key":"R14-20260911","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1007\/s11095-023-03615-9","article-title":"Cortisol as biomarker for CYP17-Inhibition is associated with therapy outcome of abiraterone acetate","volume":"40","author":"Bruin","year":"2023","journal-title":"Pharm Res"},{"key":"R15-20260911","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/FTD.0000000000000654","article-title":"Therapeutic drug monitoring of oral anticancer drugs: the Dutch pharmacology oncology group-therapeutic drug monitoring protocol for a prospective study","volume":"41","author":"Groenland","year":"2019","journal-title":"Ther Drug Monit"},{"key":"R16-20260911","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/FTD.0000000000000767","article-title":"Evaluation of extrapolation methods to predict trough concentrations to guide therapeutic drug monitoring of oral anticancer drugs","volume":"42","author":"Janssen","year":"2020","journal-title":"Ther Drug Monit"},{"key":"R17-20260911","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1634\/theoncologist.2014-0167","article-title":"Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer","volume":"19","author":"Auchus","year":"2014","journal-title":"Oncologist"},{"key":"R18-20260911","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/jamaoncol.2019.1011","article-title":"Assessment of the safety of glucocorticoid regimens in combination with abiraterone acetate for metastatic castration-resistant prostate cancer: a randomized, open-label phase 2 study","volume":"5","author":"Attard","year":"2019","journal-title":"JAMA Oncol"},{"key":"R19-20260911","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/bju.14511","article-title":"Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer","volume":"123","author":"Fenioux","year":"2019","journal-title":"BJU Int"},{"key":"R20-20260911","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s40262-024-01396-x","article-title":"Intra-individual dose escalation of abiraterone according to its plasma exposure in patients with progressive metastatic castration-resistant prostate cancer: results of the OPTIMABI trial","volume":"63","author":"Alexandre","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"R21-20260911","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/bcp.15057","article-title":"The effect of chemotherapy on the exposure-response relation of abiraterone in metastatic castration-resistant prostate cancer","volume":"88","author":"Boerrigter","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"R22-20260911","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1172\/JCI132031","article-title":"Genomics of lethal prostate cancer at diagnosis and castration resistance","volume":"130","author":"Mateo","year":"2020","journal-title":"J Clin Invest"},{"key":"R23-20260911","doi-asserted-by":"crossref","first-page":"13668","DOI":"10.1038\/ncomms13668","article-title":"Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer","volume":"7","author":"Henzler","year":"2016","journal-title":"Nat Commun"},{"key":"R24-20260911","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"R25-20260911","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1158\/1078-0432.CCR-18-1943","article-title":"TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer","volume":"25","author":"De Laere","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R26-20260911","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/pros.22583","article-title":"Functional p53 determines docetaxel sensitivity in prostate cancer cells","volume":"73","author":"Liu","year":"2013","journal-title":"Prostate"},{"key":"R27-20260911","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.clgc.2019.10.022","article-title":"TP53 gain-of-function mutations in circulating tumor DNA in men with metastatic castration-resistant prostate cancer","volume":"18","author":"Chapman","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"R28-20260911","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/bjc.2015.128","article-title":"Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone","volume":"112","author":"Salvi","year":"2015","journal-title":"Br J Cancer"},{"key":"R29-20260911","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00280-020-04133-w","article-title":"CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone","volume":"86","author":"Crucitta","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"R30-20260911","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/0008-5472.CAN-11-2079","article-title":"Common structural and epigenetic changes in the genome of castration-resistant prostate cancer","volume":"72","author":"Friedlander","year":"2012","journal-title":"Cancer Res"},{"key":"R31-20260911","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"R32-20260911","first-page":"37","article-title":"Abiraterone in metastatic castration-resistant prostate cancer: efficacy and safety in unselected patients","volume":"17","author":"Marret","year":"2018","journal-title":"Cancer Treat Res Commun"},{"key":"R33-20260911","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1158\/0008-5472.CAN-11-0532","article-title":"Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors","volume":"71","author":"Cai","year":"2011","journal-title":"Cancer Res"},{"key":"R34-20260911","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jsbmb.2009.03.011","article-title":"Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts","volume":"115","author":"Locke","year":"2009","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R35-20260911","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/pros.24297","article-title":"Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling","volume":"82","author":"Moll","year":"2022","journal-title":"Prostate"},{"key":"R36-20260911","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1038\/onc.2013.235","article-title":"Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis","volume":"33","author":"Yuan","year":"2014","journal-title":"Oncogene"},{"key":"R37-20260911","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1158\/1078-0432.CCR-11-0728","article-title":"Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants","volume":"17","author":"Mostaghel","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R38-20260911","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/pros.23799","article-title":"A bypass mechanism of abiraterone-resistant prostate cancer: accumulating CYP17A1 substrates activate androgen receptor signaling","volume":"79","author":"Moll","year":"2019","journal-title":"Prostate"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001441","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:00:48Z","timestamp":1789135248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001441","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"2025-07-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}